Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69

被引:66
作者
Imamichi, T [1 ]
Berg, SC
Imamichi, H
Lopez, JC
Metcalf, JA
Falloon, J
Lane, HC
机构
[1] NCI, Frederick Canc Res & Dev Ctr, SAIF Frederick, Lab Mol Retrovirol,Clin Serv Program, Frederick, MD 21702 USA
[2] NIAID, Immunoregulat Lab, Bethesda, MD 20892 USA
[3] Hosp Gen Gregorio Maranon, E-28007 Madrid, Spain
关键词
D O I
10.1128/JVI.74.23.10958-10964.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The combination of an amino acid deletion at codon 67 (Delta 67) and Thr-to-Gly change at codon 69 (T69G) in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is associated with high-level resistance to multiple RT inhibitors. To determine the relative contributions of the Delta 67 and T69G mutations on viral fitness, we performed a series of studies of HIV replication using recombinant variants. A high-level 3 ' -azido-3 ' -deoxythymidine (AZT)-resistant variant containing Delta 67 plus T69G/K70R/L741/KI03N/T215F/ K219Q in RT replicated as efficiently as wild-type virus (Wt). In contrast, the construct without Delta 67 exhibited impaired replication (23% of growth of Wt). A competitive fitness study failed to reveal any differences in replication rates between the Delta 67+T69G/K70R/L741/KI03N/T215F/K219Q mutant and Wt. Evaluation of proviral DNA sequences over a 3-year period in a patient harboring the multiresistant HIV revealed that the T69G mutation emerged in the context of a D67NiK70R/T215F/K219Q mutant backbone prior to appearance of the Delta 67 deletion. To assess the impact of this stepwise accumulation of mutations on viral replication, a series of recombinant variants was constructed and analyzed for replication competence. The T69G mutation was found to confer 2 ' ,3 ' -dideoxyinosine resistance at the expense of fitness. Subsequently, the development of the Delta 67 deletion led to a virus with improved replication and high-level AZT resistance.
引用
收藏
页码:10958 / 10964
页数:7
相关论文
共 45 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]  
*AIDS CLIN TRIALS, 1997, VIR MAN HIV LAB
[3]   PERSISTENCE OF AZIDOTHYMIDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA GENOTYPES IN POSTTREATMENT SERA [J].
ALBERT, J ;
WAHLBERG, J ;
LUNDEBERG, J ;
COX, S ;
SANDSTROM, E ;
WAHREN, B ;
UHLEN, M .
JOURNAL OF VIROLOGY, 1992, 66 (09) :5627-5630
[4]   3′-azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants [J].
Arts, EJ ;
Quinones-Mateu, ME ;
Albright, JL ;
Marois, JP ;
Hough, C ;
Gu, ZX ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 1998, 72 (06) :4858-4865
[5]   Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription [J].
Arts, EJ ;
Wainberg, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :527-540
[6]   Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].
Back, NKT ;
Nijhuis, M ;
Keulen, W ;
Boucher, CAB ;
Essink, BBO ;
vanKuilenburg, ABP ;
vanGennip, AH ;
Berkhout, B .
EMBO JOURNAL, 1996, 15 (15) :4040-4049
[7]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[8]   EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
BOUCHER, CAB ;
VANLEEUWEN, R ;
KELLAM, P ;
SCHIPPER, P ;
TIJNAGEL, J ;
LANGE, JMA ;
LARDER, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) :1525-1530
[9]   HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial [J].
BrunVezinet, F ;
Boucher, C ;
Loveday, C ;
Descamps, D ;
Fauveau, V ;
Izopet, J ;
Jeffries, D ;
Kaye, S ;
Krzyanowski, C ;
Nunn, A ;
Schuurman, R ;
Seigneurin, JM ;
Tamalet, C ;
Tedder, R ;
Weber, J ;
Weverling, GJ ;
Aber, V ;
Aboulker, JP ;
Babiker, AG ;
Bragman, K ;
Breckenridge, AM ;
Carbon, C ;
Charreau, I ;
Chene, G ;
Collis, P ;
Cooper, D ;
Darbyshire, JH ;
Dormont, J ;
Fiddian, P ;
Flepp, M ;
Gazzard, B ;
Goebel, FD ;
Hooker, M ;
Lange, J ;
Luthy, R ;
Peto, TEA ;
Reiss, P ;
Seligmann, M ;
Stone, AB ;
Thomis, J ;
Vella, S ;
Walckenaer, G ;
Warrell, D ;
Weller, IVD ;
Wilber, R ;
Yeni, P ;
Yeo, J ;
Withnall, R ;
Babiker, A ;
Bloch, J .
LANCET, 1997, 350 (9083) :983-990
[10]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489